1633 related articles for article (PubMed ID: 19279051)
1. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
2. Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10.
Van Heirstraeten L; Leten G; Lammens C; Goossens H; Malhotra-Kumar S
J Antimicrob Chemother; 2012 Nov; 67(11):2602-5. PubMed ID: 22815354
[TBL] [Abstract][Full Text] [Related]
3. In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types.
Billal DS; Fedorko DP; Yan SS; Hotomi M; Fujihara K; Nelson N; Yamanaka N
J Antimicrob Chemother; 2007 Jan; 59(1):28-34. PubMed ID: 17065188
[TBL] [Abstract][Full Text] [Related]
4. Emerging fluoroquinolone-non-susceptible group A streptococci in two different paediatric populations.
Smeesters PR; Vergison A; Junior DC; Van Melderen L
Int J Antimicrob Agents; 2009 Jul; 34(1):44-9. PubMed ID: 19269141
[TBL] [Abstract][Full Text] [Related]
5. Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes.
Malhotra-Kumar S; Lammens C; Chapelle S; Mallentjer C; Weyler J; Goossens H
J Antimicrob Chemother; 2005 Mar; 55(3):320-5. PubMed ID: 15705642
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
7. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
[TBL] [Abstract][Full Text] [Related]
8. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics.
Orscheln RC; Johnson DR; Olson SM; Presti RM; Martin JM; Kaplan EL; Storch GA
J Infect Dis; 2005 Apr; 191(8):1272-9. PubMed ID: 15776373
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
[TBL] [Abstract][Full Text] [Related]
12. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
Turner AK; Nair S; Wain J
J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain.
Rivera A; Rebollo M; Sánchez F; Navarro F; Miró E; Mirelis B; Coll P
Clin Microbiol Infect; 2005 Sep; 11(9):759-61. PubMed ID: 16104992
[TBL] [Abstract][Full Text] [Related]
14. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
15. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
Dalhoff A; Schubert S
Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
[TBL] [Abstract][Full Text] [Related]
16. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
17. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.
De Vecchi E; Nicola L; Ossola F; Drago L
J Antimicrob Chemother; 2009 Apr; 63(4):721-7. PubMed ID: 19218275
[TBL] [Abstract][Full Text] [Related]
18. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
[TBL] [Abstract][Full Text] [Related]
19. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Biedenbach DJ; Toleman MA; Walsh TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Jun; 55(2):119-27. PubMed ID: 16530373
[TBL] [Abstract][Full Text] [Related]
20. Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila.
Almahmoud I; Kay E; Schneider D; Maurin M
J Antimicrob Chemother; 2009 Aug; 64(2):284-93. PubMed ID: 19474069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
